Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $332.17, for a total value of $66,434.00. Following the completion of the transaction, the director now owns 936 shares of the company’s stock, valued at $310,911.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Teleflex stock traded up $6.49 on Thursday, hitting $340.48. The stock had a trading volume of 169,111 shares, compared to its average volume of 354,605. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.41 and a current ratio of 2.27. Teleflex Incorporated has a one year low of $226.02 and a one year high of $340.93. The firm has a market cap of $15.41 billion, a PE ratio of 34.39, a price-to-earnings-growth ratio of 2.20 and a beta of 1.01. The firm has a 50-day moving average of $321.20.
Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, May 2nd. The medical technology company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.17 by $0.07. Teleflex had a return on equity of 18.62% and a net margin of 7.50%. The firm had revenue of $613.60 million during the quarter, compared to analyst estimates of $608.27 million. During the same quarter in the previous year, the firm earned $2.15 EPS. Teleflex’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities analysts anticipate that Teleflex Incorporated will post 11.05 EPS for the current fiscal year.
TFX has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Raymond James restated a “market perform” rating and set a C$43.00 price target on shares of Snc-Lavalin Group in a research note on Wednesday, March 27th. Morgan Stanley reduced their target price on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a research note on Tuesday. UBS Group reiterated a “hold” rating on shares of Bayerische Motoren Werke in a research note on Friday, March 22nd. Finally, Wells Fargo & Co lowered shares of Dave & Buster’s Entertainment from an “outperform” rating to a “market perform” rating and set a $48.00 price target for the company. in a research report on Tuesday, June 11th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $333.75.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Story: Preferred Stock
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.